| 1 | Abatacept | Abatacept [36] Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (ctla4-ig); Abatacept (iv); Abatacept (sc); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept active treatment; Abatacept delayed-onset treatment; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Device: abatacept combination product (acp); Double-blind abatacept; Drug: abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Orencia® (abatacept); Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; | [1] D03203 D03203 💬 |
[2] CD80, CD86 💬 |
Allograft rejection [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
| 2 | Cyclosporine | Atg+cyclosporine [26] Atg+cyclosporine; Atg+rapamune+cyclosporine; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide,cyclosporine a; Cyclosporine; Cyclosporine (gengraf ); Cyclosporine (usan); Cyclosporine 5 mg/kg bid days 0-14; Cyclosporine a; Cyclosporine a (csa); Cyclosporine a dry powder inhalation (drug); Cyclosporine combine with mycophenolate mofetil; Cyclosporine inhalation solution; Cyclosporine inhalation solution (cis); Cyclosporine oral product; Cyclosporine pill; Cyclosporine vs infliximab; Cyclosporine-a; Device: cyclosporine a; Liposomal aerosol cyclosporine; Liposomal cyclosporine a; Liposomal cyclosporine a 10 mg; Liposomal cyclosporine a 5 mg; Oral cyclosporine; Rabbit atg, cyclosporine, levamisole; Twice-daily dosage with 0.5% cyclosporine-a eyedrops; | [1] D00184 D00184 💬 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 [43] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬 |
| 3 | Dithiopyr | - | - |
- |
- |
055 [1] 55 💬 |
| 4 | Human interleukin-2 | Anti-human interleukin-23 monoclonal antibody [3] Anti-human interleukin-23 monoclonal antibody; Human interleukin-2; Recombinant human interleukin-2 (rhil-2); | - |
- |
- |
002 [17] 2 , 13, 35, 46, 49, 51, 53, 55, 56, 60, 63, 65, 95, 96, 97, 162, 271 💬 |
| 5 | Infliximab | 99m technetium infliximab [70] 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Other: infliximab (ifx) infusion; Other: measurement of drug (adalimumab/infliximab); Procedure: measurement of serum infliximab and anti-infliximab antibodies; Procedure: treatment according to current standards without knowledge of serum infliximab and anti-infliximab ab status; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | [1] D02598 D02598 💬 |
[1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
035 [25] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬 |
| 6 | Methotrexate | Abatacept (aba) + methotrexate (mtx), double-blind (db) [113] Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Combination product: methotrexate; Cp-690,550 + methotrexate; Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids; Cyclosporin, methotrexate (gvhd prophylaxis); Dmards (methotrexate; Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate and depomedrone; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate 'lederle' tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate (stable dose); Methotrexate (tapering dose); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 10 mg; Methotrexate 10 mg tablets; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate ``lederle`` 2.5mg tablets; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate ebewe; Methotrexate hospira 2,5 mg tablety; Methotrexate hospira 2.5 mg tablety; Methotrexate injection; Methotrexate lachema 5inj. sol; Methotrexate lederle 2.5 mg tablets; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate sodium tablets 2.5mg; Methotrexate tablets; Methotrexate tablets 2.5 mg; Methotrexate treatment; Methotrexate wyeth 2,5mg; Methotrexate wyeth 2,5mg tbl.; Methotrexate ® 2.5mg tablets; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol; Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate*10mg/1,33ml 4s; Methotrexate*15mg/2ml 4sir; Methotrexate*2,5mg 25cpr; Methotrexate*20mg/2,66ml 4s; Methotrexate*25cpr 2,5mg; Methotrexate*7,5mg/ml 4sir.; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Other: methotrexate therapy; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tak-715 and methotrexate; Tak-783 and methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab plus methotrexate; Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; | [2] D00142 D00142
D02115 D02115 💬 |
[2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
011 [35] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬 |
| 7 | Rituximab | Abatacept, rituximab or tocilizumab [67] Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Abp 798 biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Double-blind rituximab; Dr. reddy’s rituximab (drl_ri) 100mg; Dr. reddy’s rituximab (drl_ri) 500mg; Eltrombopag combining rituximab; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Prednisone, low dose rituximab; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (inn: rituximab), brand name in the us; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (eu); Rituximab (genetical recombination); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab (us); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Sait101 (rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab; [rituximab]; | [1] D02994 D02994 💬 |
[1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
011 [47] 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
| 8 | Tiotropium | Tiotropium [14] Tiotropium; Tiotropium bromide; Tiotropium bromide (monohydrate); Tiotropium bromide 5 mcg; Tiotropium bromide high; Tiotropium bromide low; Tiotropium bromide medium; Tiotropium bromide monohydrate; Tiotropium bromide-low dose-2.5mcg; Tiotropium respimat; Tiotropium respimat 1.25 microgram solution for inhalation; Tiotropium respimat 1.25 microgram, solution for inhalation; Tiotropium respimat 1.25 micrograms solution for inhalation; Tiotropium respimat® inhaler; | - |
- |
- |
055 [3] 55, 85, 299 💬 |
| 9 | Tocilizumab | Abatacept, rituximab or tocilizumab [39] Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra or roactemra); Tocilizumab (actemra); Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab (tcz); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab 162mg/0.9ml sc pfs sc; Tocilizumab 162mg/0.9ml syringe sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab and iv steroids combination; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab iv; Tocilizumab plus methotrexate; Tocilizumab prefilled syringe; Tocilizumab roche; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml disposable auto-injector (ai); Tocilizumab sc 162 mg/0.9 ml pre-filled syringe with safety device (pfs); Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; | [1] D02596 D02596 💬 |
[1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 [18] 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬 |